Literature DB >> 20083260

Discrepancy between local and central pathological review of radical prostatectomy specimens.

Kentaro Kuroiwa1, Taizo Shiraishi, Osamu Ogawa, Michiyuki Usami, Yoshihiko Hirao, Seiji Naito.   

Abstract

PURPOSE: Pathological assessment of radical prostatectomy specimens has not been uniform among pathologists. We investigated interobserver variability of radical prostatectomy specimen reviews between local and central pathologists.
MATERIALS AND METHODS: We collated data from 50 institutions on 2,015 patients with cT1c-3 prostate cancer who underwent radical prostatectomy between 1997 and 2005. All radical prostatectomy specimens were retrospectively reevaluated by a central uropathologist. Gleason score, extracapsular extension, seminal vesicle invasion, lymph node involvement, positive surgical margin, year of diagnosis and pathology volume were recorded.
RESULTS: The exact concordance rate of Gleason score between local and central review was 54.8%, and under grading and over grading rates at local review were 25.9% and 19.2%, respectively. Spearman's rank correlation coefficient was 0.61 for local and central radical prostatectomy Gleason score. The exact concordance rate of Gleason score 8-10 at local review was significantly lower than that of Gleason score 5-6, 3 + 4 and 4 + 3 at local review (p = 0.011, <0.001 and 0.006). Exact concordance rates between local and central review for extracapsular extension, seminal vesicle invasion, lymph node involvement and positive surgical margin were 82.5%, 97.6%, 99.6% and 87.5%, respectively. High volume institutions and recently diagnosed cohorts showed significantly higher exact concordance rates between local and central review for radical prostatectomy Gleason score and other pathological features (all p <0.001).
CONCLUSIONS: High volume institutions and recent series show higher concordance between local and central review of radical prostatectomy pathology. However, concordance for high grade Gleason score, extracapsular extension and surgical margin status remains poor. Radical prostatectomy specimens should be reevaluated in a multi-institutional study for more accurate pathological data. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20083260     DOI: 10.1016/j.juro.2009.11.024

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

2.  Concordance of Gleason grading with three-dimensional ultrasound systematic biopsy and biopsy core pre-embedding.

Authors:  Anouk A M A van der Aa; Christophe K Mannaerts; Hans van der Linden; Maudy Gayet; Bart Ph Schrier; Massimo Mischi; Harrie P Beerlage; Hessel Wijkstra
Journal:  World J Urol       Date:  2018-02-01       Impact factor: 4.226

3.  [Documentation quality of histopathology reports of prostate needle biopsies: a snapshot].

Authors:  S Biesterfeld
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

4.  Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.

Authors:  Jesse D Le; Samuel Stephenson; Michelle Brugger; David Y Lu; Patricia Lieu; Geoffrey A Sonn; Shyam Natarajan; Frederick J Dorey; Jiaoti Huang; Daniel J A Margolis; Robert E Reiter; Leonard S Marks
Journal:  J Urol       Date:  2014-05-01       Impact factor: 7.450

5.  Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 multinational clinical trial.

Authors:  George J Netto; Mario Eisenberger; Jonathan I Epstein
Journal:  Urology       Date:  2010-12-13       Impact factor: 2.649

6.  The clinical impact of pathological review on selection the treatment modality for localized prostate cancer in candidates for brachytherapy monotherapy.

Authors:  Ryo Kishimoto; Takashi Saika; Kensuke Bekku; Hiroyuki Nose; Fernando Abarzua; Yasuyuki Kobayashi; Motoo Araki; Hiroyuki Yanai; Yasutomo Nasu; Hiromi Kumon
Journal:  World J Urol       Date:  2011-08-17       Impact factor: 4.226

7.  Influence of pathologist experience on positive surgical margins following radical prostatectomy.

Authors:  Jacob E Tallman; Vignesh T Packiam; Kristen E Wroblewski; Gladell P Paner; Scott E Eggener
Journal:  Urol Oncol       Date:  2017-03-13       Impact factor: 3.498

8.  Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.

Authors:  Andreas G Wibmer; Ines Nikolovski; Joshua Chaim; Yulia Lakhman; Robert A Lefkowitz; Evis Sala; Sigrid V Carlsson; Samson W Fine; Michael W Kattan; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

9.  Gleason scoring at a comprehensive cancer center: what's the difference?

Authors:  Natasha C Townsend; Karen Ruth; Tahseen Al-Saleem; Eric M Horwitz; Mark Sobczak; Robert G Uzzo; Rosalia Viterbo; Mark K Buyyounouski
Journal:  J Natl Compr Canc Netw       Date:  2013-07       Impact factor: 11.908

10.  International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer.

Authors:  Andreas G Wibmer; Michael W Kattan; Francesco Alessandrino; Alexander D J Baur; Lars Boesen; Felipe Boschini Franco; David Bonekamp; Riccardo Campa; Hannes Cash; Violeta Catalá; Sebastien Crouzet; Sounil Dinnoo; James Eastham; Fiona M Fennessy; Kamyar Ghabili; Markus Hohenfellner; Angelique W Levi; Xinge Ji; Vibeke Løgager; Daniel J Margolis; Paul C Moldovan; Valeria Panebianco; Tobias Penzkofer; Philippe Puech; Jan Philipp Radtke; Olivier Rouvière; Heinz-Peter Schlemmer; Preston C Sprenkle; Clare M Tempany; Joan C Vilanova; Jeffrey Weinreb; Hedvig Hricak; Amita Shukla-Dave
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.